One Global Service Provider has delivered remarkable returns of 5,945% over five years, transforming a ₹1 lakh investment into ₹60 lakhs. According to reports from The Financial Express, the company's share price surged from approximately ₹9 in June 2021 to ₹544 as of June 5, 2026. The healthcare services firm, incorporated in 1992, operates in life sciences and healthcare solutions globally, with expertise in mass screening, diagnostics, and related sciences for hospitals and government bodies.
The company has demonstrated exceptional financial growth with sales expanding from ₹4 crore in FY21 to ₹498 crore in FY26, representing a 162% compound annual growth rate (CAGR). As reported by The Financial Express, net profit grew from approximately ₹2 crore in FY21 to ₹70 crore in FY26, achieving a 104% CAGR. EBITDA also showed strong performance, growing from ₹2 crore to ₹93 crore over the same period, with a 116% CAGR. The growth trajectory shows consistent upward momentum across all financial metrics, with the company maintaining its position as a high-growth healthcare services provider.
One Global Service Provider stands out with an 87% return on capital employed (ROCE), significantly higher than the industry median of 22%. According to The Financial Express, the company also achieves a 65% return on equity (ROE) and maintains almost debt-free operations with minimal borrowings. This capital efficiency allows the company to reinvest profits for business growth or distribute to shareholders through dividends, though the company currently does not pay dividends despite reporting consistent profits. The company's ability to generate such high returns on capital demonstrates exceptional operational efficiency and business model strength.
The stock trades at a PE ratio of 15x, substantially below the industry median of 47x, with the 10-year median PE at 16x versus the industry median of 26x. However, as reported by The Financial Express, the company faces challenges including a 159-day debtor cycle where customers take over five months to settle bills, and significant shareholding changes with promoter holding increasing from 15% in March 2025 to 68.4% in March 2026 following a merger. The stock also sits under additional surveillance, which can limit trading flexibility.
While the company demonstrates strong fundamentals with zero debt and high capital efficiency, The Financial Express notes that the growth base remains small and untested, and the stock trades under additional surveillance which can limit trading. The analysis suggests that while clean balance sheets and high ROCE indicate business quality, they don't guarantee appropriate entry pricing, emphasizing the importance of careful monitoring rather than aggressive chasing of multibagger opportunities. The company's recent earnings growth, while impressive, requires careful evaluation of sustainability and the impact of its reshuffled shareholding structure.
